Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00208702
Status:
COMPLETED
Last Update Posted:
2015-11-17
First Post:
2005-09-13
Brief Title:
Thyroid Medication and Antidepressants for Treating Major Depression
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Thyroid Axis in Major Depression
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness of treatment with supplemental triiodothyronine T3 Cytomel and sertraline Zoloft a selective serotonin reuptake inhibitor SSRI in improving symptoms of major depressive disorder MDD
Detailed Description:
The primary hypothesis is that triiodothyronine Cytomel supplementation of the antidepressant sertraline Zoloft will result in a greater improvement in HAM-D scores compared to placebo in the treatment of Major Depressive Disorder MDD
The goals of this proposal are to examine the relationship between Major Depressive Disorder MDD and abnormalities of the hypothalamic pituitary thyroid HPT axis This protocol will systematically examine the value of supplemental triiodothyronine T3 Cytomel with sertraline Zoloft a selective serotonin reuptake inhibitor SSRI in the treatment of MDD The focus will be on two overlapping populations 1 those with evidence of HPT abnormalities and 2 those who did not respond to a previous adequate SSRI trial
The goals of this proposal are to examine the relationship between Major Depressive Disorder MDD and abnormalities of the hypothalamic pituitary thyroid HPT axis This protocol will systematically examine the value of supplemental triiodothyronine T3 Cytomel with sertraline Zoloft a selective serotonin reuptake inhibitor SSRI in the treatment of MDD The focus will be on two overlapping populations 1 those with evidence of HPT abnormalities and 2 those who did not respond to a previous adequate SSRI trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DSIR AT-SO | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH056946 |
| R01MH056946 | NIH | None | None |
| 431-1996 | None | None | None |